AAAAAA

   
Results: 1-7 |
Results: 7
Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens
Authors: van der Burg, SH Kwappenberg, KMC O'Neill, T Brandt, RMP Melief, CJM Hickling, JK Offringa, R
Citation: Sh. Van Der Burg et al., Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens, VACCINE, 19(27), 2001, pp. 3652-3660
Peptide vaccines
Authors: Yang, D Holt, GE Rudolf, MP Velders, MP Brandt, RMP Kwon, ED Kast, WM
Citation: D. Yang et al., Peptide vaccines, MED INTEL U, 26, 2001, pp. 214-226
Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma
Authors: Ressing, ME van Driel, WJ Brandt, RMP Kenter, GG de Jong, JH Bauknecht, T Fleuren, GJ Hoogerhout, P Offringa, R Sette, A Celis, E Grey, H Trimbos, BJ Kast, WM Melief, CJM
Citation: Me. Ressing et al., Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma, J IMMUNOTH, 23(2), 2000, pp. 255-266
Critical dependence of the peptide delivery method on the efficacy of epitope focused immunotherapy
Authors: Holt, GE Velders, MP Rudolf, MP Small, LA Provenzano, M Weijzen, S Da Silva, DM Visser, M ter Horst, SAJ Brandt, RMP Kast, WM
Citation: Ge. Holt et al., Critical dependence of the peptide delivery method on the efficacy of epitope focused immunotherapy, MED INTEL U, 24, 2000, pp. 56-72
Peptides in cervical cancer
Authors: Ressing, ME Brandt, RMP de Jong, JH Offringa, R Melief, CJM Kast, WM
Citation: Me. Ressing et al., Peptides in cervical cancer, MED INTEL U, 24, 2000, pp. 172-189
Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: Clinical evaluation of a phase I-II trial
Authors: van Driel, WJ Ressing, ME Kenter, GG Brandt, RMP Krul, EJT van Rossum, AB Schuuring, E Offringa, R Bauknecht, T Tamm-Hermelink, A van Dam, PA Fleuren, GJ Kast, WM Melief, CJM Trimbos, JB
Citation: Wj. Van Driel et al., Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: Clinical evaluation of a phase I-II trial, EUR J CANC, 35(6), 1999, pp. 946-952
Differential binding of viral peptides to HLA-A2 alleles. Implications forhuman papillomavirus type 16 E7 peptide-based vaccination against cervicalcarcinoma
Authors: Ressing, ME de Jong, JH Brandt, RMP Drijfhout, JW Benckhuijsen, WE Schreuder, GMT Offringa, R Kast, WM Melief, CJM
Citation: Me. Ressing et al., Differential binding of viral peptides to HLA-A2 alleles. Implications forhuman papillomavirus type 16 E7 peptide-based vaccination against cervicalcarcinoma, EUR J IMMUN, 29(4), 1999, pp. 1292-1303
Risultati: 1-7 |